http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#Head
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#provenance
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#pubinfo
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion
http://purl.obolibrary.org/obo/DOID_3908
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3908
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00530
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
http://www.w3.org/2000/01/rdf-schema#label
erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00530
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#provenance
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#pubinfo
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig
http://purl.org/nanopub/x/hasSignature
ANZ9f2Iibw4BE+OPoztuDipJkIp+6xTk+HHCC146oC8/FeUAw2CZWhGLFiULasM2ExJjh+F8Dnkuf8h75TPMyJSWEdRxMdTXlIzeLtcM6XmgcC5XOVyFpHYQ9Ka7Z3MVXTSDVnNv5fwjUFZm1JBg0vXXhz1Bl7Mnt0sigYWkiCY=
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://purl.org/dc/terms/created
2021-06-15T18:17:22.636+02:00
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs